Prestige Biologics Achieves Record-High Quarterly Results
Prestige Biologics has surpassed 10 billion won in quarterly sales for the first time.
According to Prestige Biologics on August 19, revenue for the fourth quarter of fiscal year 2026 (April to June 2026) reached 11.47 billion won. This figure is more than five times higher than the previous quarter's sales of 2.27 billion won.
During fiscal year 2026, Prestige Biologics signed a total of six new contract manufacturing (CDMO) agreements with domestic and international clients, amounting to approximately 41.2 billion won. The company has continued to expand its order base, and these new contracts have been sequentially converted into production and sales, positively impacting this quarter’s performance.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jinwoo Kim, CEO of Prestige Biologics, stated, "Despite the sales growth, the increase in losses was primarily due to impairment of inventory assets, convertible bonds (CB), and certain production facilities. The actual impact on cash flow is limited. Surpassing 10 billion won in fourth-quarter sales demonstrates that our ongoing expansion of the order base is now being reflected in our results."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.